Skip to Main content Skip to Navigation
New interface
Journal articles

Complement System: a Neglected Pathway in Immunotherapy

Abstract : Approved for the treatment of autoimmune diseases, hematological malignancies, and solid cancers, several monoclonal antibodies (mAb) make use of complement in their mechanism of action. Such an assessment is based on comprehensive investigations that used mouse models, in vitro studies, and analyses from patients at initiation (basal level to highlight deficiencies) and after treatment initiation (mAb impact on complement), which have further provided key insights into the importance of the complement activation and/or complement deficiencies in mAb activity. Accordingly, new approaches can now be developed with the final objective of increasing the clinical efficacy of mAb. These improvements include (i) the concurrent administration of fresh frozen plasma during mAb therapy; (ii) mAb modifications such as immunoglobulin G subclass switching, Fc mutation, or IgG hexamerization to improve the fixation and activation of C1q; (iii) optimization of the target recognition to induce a higher complement-dependent cytotoxicity (CDC) and/or complement-dependant cellular cytotoxicity (CDCC); and (iv) the control of soluble and cellular complement inhibitors.
Document type :
Journal articles
Complete list of metadata
Contributor : Geneviève Michel Connect in order to contact the contributor
Submitted on : Tuesday, June 4, 2019 - 3:55:39 PM
Last modification on : Tuesday, November 29, 2022 - 5:10:07 PM




Anne Bordron, Cristina Bagacean, Adrian Tempescul, Christian Berthou, Eléonore Bettachioli, et al.. Complement System: a Neglected Pathway in Immunotherapy. Clinical Reviews in Allergy and Immunology, 2019, ⟨10.1007/s12016-019-08741-0⟩. ⟨hal-02147331⟩



Record views